EuroPCR 2022 | ASTRO TAVR: Should we treat post TAVR Strokes with Neurointervention?

The presence of stroke after TAVR has dropped and is currently at 2%; however, it is 5 times more deadly, has negatively affected quality of life and has increased healthcare costs. 

EuroPCR 2022 | Cambios en el daño cardíaco luego del reemplazo valvular aórtico por cirugía

The ASTRO TAVI registry included 14 centers and 16615 TAVR procedures between 2006 y 2021. In this period, there were 484 neurological events within 30 days after procedure (2.9%). 387 of these events were ischemic strokes (2.3%) and 93 were excluded for lack of data, leaving 276 patients for analysis. Patients were either treated conservatively (CT) or received a neuro-intervention (NI) with thrombolysis or mechanical thrombectomy.

Primary end point was all cause mortality at 1 year and neurological disability at 90 days was assessed with the modified Rankin score.

Stroke was mild (NIHSS 0-5) in 149 patients (146 CT and 3 NI), moderate (NIHSS 6-15) in 71 (CT 56 and NI 15) and severe (NIHSS 16-42) in 74 (53 CT and 21 NI).

Most strokes presented within 48 hours, morality was higher in patients with severe stroke vs. moderate or mild, both at 30 days and 12 months. (57.6% vs. 18.4% vs.9% p<0.0001 and 77.5% vs. 36% vs. 29% p<0.0001).

Read also: EuroPCR 2022 | Changes in Cardiac Damage after Surgical Aortic Valve Replacement.

Where comparing patient treatments, there were no differences between patients with moderate and severe stoke. Neither were there differences when looking at aortic valve area, mean gradient and left ventricular function, which was conserved. Mean age was 81, 31% were diabetic, 71% hypertensive, 17% had COPD, 1,4 mg/L creatinine. 

Cerebroprotection was used in 6%, 80% were treated via femoral and 68% of valves were self-expanding. 

Mortality STS Score was 5.8%.

Read also: Transfemoral vs Transradial Approach in the Percutaneous Treatment of CTO.

General anesthesia was more frequent in patients receiving CT (43.5% vs 15.4% p=0.001).

At 12 months, even though there were no differences in mortality, there was lower neurological disability in patients undergoing neuro intervention at 90 days. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the editorial board of SOLACI.org.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...

Can Coronary CT Angiography Replace Invasive Coronary Angiography in Pre-TAVI Coronary Assessment?

Coronary artery disease coexists in approximately half of patients undergoing transcatheter aortic valve implantation, making coronary assessment prior to the procedure essential. Invasive coronary...

Valve-in-Valve in Small Surgical Aortic Bioprostheses: Balloon-Expandable or Self-Expanding? Three-Year Results from the LYTEN Trial

Dysfunction of small surgical aortic bioprostheses represents a challenging scenario for transcatheter aortic valve replacement in the valve-in-valve setting, due to the higher incidence...

Can TAVI Be Safely Performed in Patients With Bicuspid Aortic Valve?

Bicuspid aortic valve (BAV) represents an anatomical challenge for transcatheter aortic valve replacement (TAVR) due to the frequent presence of elliptical annuli, fibroc calcific...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

OCT- and IVUS-Guided Coronary Angioplasty in Acute Coronary Syndrome: Long-Term Clinical Outcomes

Percutaneous coronary angioplasty (PCI) in patients with acute coronary syndrome (ACS) has reduced mortality in the acute phase. However, recurrent ACS and target vessel...

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...